Provided by Tiger Trade Technology Pte. Ltd.

Artelo Biosciences, Inc.

1.30
+0.06004.84%
Volume:50.00K
Turnover:66.62K
Market Cap:2.76M
PE:-0.07
High:1.40
Open:1.24
Low:1.24
Close:1.24
52wk High:28.60
52wk Low:1.10
Shares:2.12M
Float Shares:2.01M
Volume Ratio:1.05
T/O Rate:2.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-19.5000
EPS(LYR):-18.2923
ROE:-436.14%
ROA:-136.26%
PB:-4.36
PE(LYR):-0.07

Loading ...

Garden Stage Receives NASDAQ Non-Compliance Notice

Deep News
·
Sep 08, 2025

Artelo Biosciences Cut to Hold From Buy by D. Boral Capital

Dow Jones
·
Sep 08, 2025

Leading Broad-Based Index Performer! 双创龙头ETF (588330) Underlying Index Surges Over 34% in Past Month! Can China's "NASDAQ" Continue Rising?

Deep News
·
Sep 08, 2025

BRIEF-Artelo Biosciences Announces Closing Of $3.0 Million Public Offering

Reuters
·
Sep 06, 2025

Nasdaq Proposes Higher Listing Requirements as Deloitte Questions Impact on Chinese Companies' Hong Kong Migration

Stock News
·
Sep 05, 2025

Nasdaq Gains Over 100 Points; Science Applications Shares Fall After Q2 Results

Benzinga
·
Sep 05, 2025

BUZZ-U.S. STOCKS ON THE MOVE- Gap, Aquestive Therapeutics, Lumentum

Reuters
·
Sep 04, 2025

Artelo Biosciences Shares Tumble 51% After Co Prices Stock Offering

THOMSON REUTERS
·
Sep 04, 2025

Artelo Biosciences Prices $3 Million Offering; Shares Fall 50% Pre-Bell

MT Newswires Live
·
Sep 04, 2025

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

THOMSON REUTERS
·
Sep 04, 2025

Artelo Biosciences Inc - Prices Public Share Offering at $4.40 per Share

THOMSON REUTERS
·
Sep 04, 2025

BRIEF-Artelo Biosciences Announces Proposed Underwritten Public Offering

Reuters
·
Sep 04, 2025

Nasdaq Verafin Partners with BioCatch to Combat Payment Fraud

Deep News
·
Sep 03, 2025

BRIEF-Artelo Biosciences Announces Positive Interim Phase 2 Cares Results For The Treatment Of Cancer Anorexia-Cachexia Syndrome (Cacs)

Reuters
·
Sep 03, 2025

Artelo Biosciences Inc - +6.4% Weight Gain at 12 Weeks VS −5.4% Loss on Placebo in Interim Phase 2 Cares Study

THOMSON REUTERS
·
Sep 03, 2025

Artelo Biosciences Inc - Safety Results Show Art27.13 Well Tolerated

THOMSON REUTERS
·
Sep 03, 2025

Artelo Biosciences Announces Positive Interim Phase 2 Cares Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (Cacs)

THOMSON REUTERS
·
Sep 03, 2025

Beijing Originwater Intelligent Technology Receives Regulatory Feedback on NASDAQ Listing: Required to Clarify Relationship with A-Share ChiNext Company Beijing Originwater Technology Co., Ltd.

Deep News
·
Sep 02, 2025

Artelo Biosciences Inc. Conducted Special Meeting of Stockholders

Reuters
·
Aug 30, 2025